Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Age-specific mortality rates
- UK audit - cases
- Role of HPV testing in cervical screening (1)
- Role of HPV testing in cervical screening (2)
- "HPV testing is at least as good"
- Baseline results of HPV testing
- Aims
- Studies included
- HPV positivity by age - common shape
- Cytology sensitivity - CIN2+ (all ages)
- HPV sensitivity - CIN2+ (all ages)
- Cytology positivity - normal (all ages)
- HPV positivity - normal (all ages)
- HPV positivity - normal (ages = or more than 35)
- Summary
- Subsequent studies
- Double-testing studies after overview
- Randomised trials - first round
- Long-term follow-up of HPV testing
- Cumulative incidence of CIN2+
- Cumulative incidence rate for CIN3+
- Conclusions
- Proposed new screening algorithm
- HPV typing
- mRNA testing
- Other potential adjunctive tests
- Potential future screening algorithm
Topics Covered
- Cases of cervical cancer in the UK
- Potential role of HPV testing in cervical screening
- Baseline results of HPV testing in European and North American screening studies
- HPV positivity by age
- Cytology sensitivity and positivity
- HPV sensitivity and positivity
- Double-testing studies
- Randomized trials
- Long-term follow-up of HPV testing: results from the Hammersmith study
- Proposed new screening algorithm
- HPV typing
- mRNA testing
- Other potential adjunctive tests
- Potential future screening algorithm
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cuzick, J. (2010, July 15). Can HPV testing be the sole primary cervical screening modality? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/DKSA5204.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jack Cuzick has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.